RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Beijing-based Shuidichou completed a $74 million Series B funding round led by internet giant Tencent Holdings to support its internet health insurance programs. Founded in 2016, Shuidichou operates three separate businesses: a medical cost crowdfunding platform, an online medical community and a medical insurance platform. The company’s services are aimed at third, fourth and fifth tier China cities. Its medical cost crowdfunding site, which the company describes as free, has raised $1.8 billion for over 1 million people.
Source: China Biotoday
